Posted by Michael Wonder on 26 Jun 2021
Vertex announces new portfolio reimbursement agreement in Italy including Kaftrio, Symkevi and additional indications of Orkambi and Kalydeco for eligible patients with cystic fibrosis
25 June 2021 - Reimbursement agreement also includes certain future indication extensions across all Vertex cystic fibrosis medicines.
Vertex Pharmaceuticals today announced it has reached a new portfolio agreement with the Italian Medicines Agency, AIFA, for the reimbursement of all of Vertex’s approved medicines for the treatment of cystic fibrosis, including Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor.
